The re-adoption by the European Medicines Agency's CHMP of its positive opinion for AstraZeneca PLC's hyperkalemia therapy, Lokelma (ZS-9, sodium zirconium cyclosilicate), if confirmed in the coming months or so by the European Commission, is expected to lead to the UK big pharma making inroads in the sector for new hyperkalemia therapies that Vifor Pharma Group has so far had to itself with its own new product, Veltassa (patiromer).
AstraZeneca's Lokelma To Join Veltassa In Hyperkalemia Sector
The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.
